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Initially thought as being non-immunogenic, recombinant AAVs have emerged as efﬁcient
vector candidates for treatingmonogenic diseases. It is now clear however that they induce
potent immune responses against transgene products which can lead to destruction of
transduced cells.Therefore, developing strategies to circumvent these immune responses
and facilitate long-term expression of transgenic therapeutic proteins is a main challenge in
gene therapy.We evaluated herein a strategy to inhibit the undesirable immune activation
that follows muscle gene transfer by administration of CTLA-4/Ig to block the costimu-
latory signals required early during immune priming and by using gene transfer of PD-1
ligands to inhibit T cell functions at the tissue sites. We provide the proof of principle that
this combination immunoregulatory therapy targeting two non-redundant checkpoints of
the immune response, i.e., priming and effector functions, can improve persistence of
transduced cells in experimental settings where cytotoxic T cells escape initial blockade.
Therefore, CTLA-4/Ig plus PD-L1/2 combination therapy represents a candidate approach
to circumvent the bottleneck of immune responses directed toward transgene products.
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INTRODUCTION
Since the original reports describing the use of adeno-associated
virus (AAV) vectors for transfer of β-galactosidase gene to muscle
(Kessler et al., 1996; Xiao et al., 1996; Fisher et al., 1997), recombi-
nant AAVs (rAAV) have emerged as very efﬁcient and potentially
non-immunogenic vector candidates for delivering therapeutic
genes to a variety of tissues and treating monogenic diseases.
As they poorly activate innate immunity and weakly transduce
dendritic cells, rAAV appear as far less immunogenic than ade-
noviral vectors (Zhang et al., 2000; Zaiss et al., 2002; McCaffrey
et al., 2008). Nevertheless, it has rapidly become clear that rAAV
vectors carrying various transgenes can, under different condi-
tions, induce potent immune responses that could ultimately lead
to destruction of transduced cells in vivo and consecutive dis-
appearance of transgene expression (Manning et al., 1997, 1998;
Halbert et al., 1998; Brockstedt et al., 1999). Not surprisingly
therefore, their use has even been proposed in genetic vaccina-
tion protocols aimed at eliciting cellular and humoral immune
responses against different microorganisms (Kuck et al., 2006;
Du et al., 2008). In primates and humans, rAAV administration
has also been documented to elicit signiﬁcant cytotoxic CD8+ T
cell responses directed against the viral as well as the transgenic
“exogenous” proteins, resulting in the destruction of transduced
cells and complete loss of transgene expression (Manno et al.,
2006; Mingozzi et al., 2007; Gao et al., 2009). Additionally, on
the side of the humoral immunity, production of neutralizing
antibodies targeting capsid proteins may also prevent vector read-
ministration and accelerate the loss of the therapeutic protein
through the formation of immune complexes. Such immune com-
plexes may further sensitize the cellular immune response by
enhancing cross-presentation of the transgenic protein by the
antigen-presenting cells (APC). Therefore, developing strategies
to circumvent immune responses and facilitate long-term expres-
sion of transgenic therapeutic proteins has been identiﬁed as one
of today’s main challenges for the translation of rAAV vectors
into the clinic (Mingozzi and High, 2011a,b; Nayak and Herzog,
2011).
Depending on the experimental situation, rAAV-mediated gene
transfer can either lead to durable transgene expression or, con-
versely, to the rapid formation of neutralizing antibodies and/or
destruction of transduced cells by cytotoxic cells. Several fac-
tors inﬂuencing the immune response against transgenic proteins
encoded by the rAAV vectors have now been identiﬁed including
host species, route of administration, vector dose, immunogenic-
ity of the transgenic protein, inﬂammatory status of the host
and capsid serotype (Mays and Wilson, 2011). These factors are
thought to inﬂuence immunogenicity by triggering innate immu-
nity, cytokine production, APC maturation, antigen presentation
and, ultimately, priming of naïve T lymphocytes to functional
effectors. Therefore, the idea to dampen immune activation by
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interfering with these very mechanisms has logically emerged
with the aim to induce a short-term immunosuppression, avoid
the early immune priming that follows vector administration and
promote long-term tolerance (Zaiss and Muruve, 2008).
Here, we evaluated two different strategies to inhibit the unde-
sirable immune activation that follows muscle gene transfer by
acting at two different checkpoints of the immune response, i.e.,
on T cell priming or on the functions of activated T cells that
may escape such priming blockade. We used the administration
of CTLA-4/Ig to inhibit the substantial immune priming that
immediately follow vector injection. Indeed, CTLA-4/Ig represent
a potent immunosuppressive fusion protein that reversibly pre-
vents T cell activation (Wallace et al., 1995) and is now used in the
clinic to treat inﬂammatory diseases such as rheumatoid arthritis
(Bluestone et al., 2006). Its immunomodulatory action depends on
its competitive inhibitory effect on the CD28/B7 pathway thereby
preventing the pivotal CD28-dependent costimulation required
to fully activate T lymphocytes (Salomon and Bluestone, 2001).
As a second strategy, we turned to immunomodulatory mole-
cules that could protect transduced muscle ﬁbers from immune
attacks by activated T cells. For that, we aimed at stimulating the
inhibitory PD-1 molecule expressed on T cells upon activation,
by the gene transfer of its ligands PD-L1 or PD-L2 to muscle cells
(Freeman et al., 2000; Latchman et al., 2001; Ishida et al., 2002).We
show herein that acting on these two non-redundant mechanisms
of tolerance provides synergistic effects that prolong transgene
expression in muscle even in the presence of circulating cytotoxic
T cells directed against the transgene product.
MATERIALS AND METHODS
ANIMAL EXPERIMENTS
Female C57BL/6 (B6) mice were obtained from Centre d’Elevage
Janvier (Le Genest Saint Isle, France). Mice were all between
7 and 10weeks of age at beginning of experiments. For trans-
duction with rAAV vectors, mice back legs were shaved under
general anesthesia and titrated 1× 1011 vector genomes (vg)
rAAV2/1-Ova or rAAV2/8-Ova were injected (50μl in PBS) in the
gastrocnemius muscles. Where indicated, 1011 vg rAAV2/1-PD-
L1 or rAAV2/1-PD-L2 were mixed with 1011 vg rAAV-Ova and
co-injected using the same procedure. For costimulation block-
ade experiments, mice were injected i.p. with 200μg CTLA-4/Ig
(Chimerigen laboratories, MF-110A4) diluted in 200μl of PBS.
In some experiments, lymphocytes from tolerized mice were
transferred to conditioned recipients to further evaluate the pres-
ence of anti-Ova lymphocytes and to study their functionality
in vivo. For that, 50× 106 splenocytes harvested from individ-
ual mice that have be treated 80 days before with AAV-Ova, with
or without immunomodulatory regimens, were injected i.v. into
5 Gy-irradiated syngenic C57BL/6 recipient. One day after, each
individual mouse was shaved and injected subcutaneously with
1× 106 syngenic EG7 tumor cells expressing the Ova antigen and
known to be sensitive in vivo to CD8+ T cell cytotoxicity in primed
animals (Moore et al., 1988). Tumor sizes were measured with a
digital caliper three times a week during 26 days. Tumor volume
was calculated as length×width× [(length+width)/2].
All animal experiments were approved by the local institu-
tional ethic committee for animal experimentation (authorization
#0211-22 “Comité Régional d’Éthique en Expérimentation Ani-
male de Normandie”).
PLASMIDIC CONSTRUCTS AND PREPARATION OF RECOMBINANT AAV
VECTORS
The rAAV-Ova vector, a kind gift of Roland W. Herzog, was
described previously (Wang et al., 2005). The cDNA encoding
mouse PD-L1 (CD274) or PD-L2 (CD273) were cloned using
standard molecular biology procedures and introduced in the
SSV9–CAG plasmidic backbone after digestion with EcoRI. The
resulting expression cassette, ﬂanked by AAV serotype 2 inverted
terminal repeats (ITRs), contains the CAG promoter combining
the cytomegalovirus early enhancer and the chicken β-actin pro-
moter, a chicken β-actin intron, and a rabbit β-globin polyadeny-
lation signal. rAAV2/1 and rAAV2/8 vectors were generated using
a standard helper-virus free three-plasmid transient transfection
method and pseudotyped with either AAV1 or AAV8 capsid pro-
teins. Vectors were puriﬁed by two cesium chloride gradient
centrifugations and dialyzed against PBS as described (Salvetti
et al., 1998). Genome titers of vector preparations were assayed
by Dot-blot hybridization using a probe to detect the CAG or
CMV promoter.
sOVA AND ANTI-OVA IgG ELISA
Quantiﬁcation of soluble Ova (sOVA) concentration in serum was
performed by Ova-speciﬁc ELISA. Microtiter plates were coated
with polyclonal rabbit anti-Ova antibodies (1:3000 dilution, Ray-
Biotech) and bound sOVA was detected using biotinylated rab-
bit polyclonal anti-Ova antibodies (1:5000 dilution, Abcam) and
streptavidin–peroxidase (1:15000, Roche).
Detection of serum anti-Ova IgG antibodies was performed by
ELISA using Ova-coated microtiter plates. Anti-Ova IgG antibod-
ies were detected using biotinylated polyclonal goat anti-mouse
IgG and revealed using the mouse ExtrAvidin kit (Sigma-Aldrich).
IgG titers were deﬁned as the dilution yielding the half maximum
optical density obtained with control serums and was calculated
using sigmoid curve ﬁtting using GraphPad prism software.
QUANTIFICATION OF Ova cDNA AND mRNA IN TRANSDUCED MUSCLES
To analyze the quantities of Ova DNA and Ova mRNA present
in transduced muscles of treated mice at indicated time points, a
real-time PCR assay was developed. Muscles collected from each
mouse were kept at −80˚C before DNA and RNA extraction per-
formed using the phenol/chloroform method and the RNeasy
Fibrous Tissue Mini Kit (Qiagen) following the manufacturer’s
instructions.
For quantiﬁcation of Ova DNA, the primers used were Ova-
F (5′-AAG CAG GCA GAG AGG TGG TA-3′), Ova-R (5′-GAA
TGG ATG GTC AGC CCT AA-3′), CD8a-F (5′-GGT GCA TTC
TCA CTC TGA GTT CC-3′), and CD8a-R (5′-GCA GAC AGA
GCT GAT TTC CTA TGT G-3′). For all reaction mixtures, 10μl
of FastStart Universal SYBR green master mix (Roche) was used
in a ﬁnal volume of 20μl. Ova primers were used at 500 nM
and CD8a primers at 400 nM. Approximately 10 ng of DNA was
added in a 5-μl volume and always set up in duplicate. Each qPCR
was performed under the following conditions: 10min hot-start
denaturation at 95˚C and 40 ampliﬁcation cycles (10 s at 95˚C,
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30 s at 60˚C). The melting temperatures of the ﬁnal double-strand
DNA products were determined by gradual heating from 60 to
95˚C over 20min. All qPCRs were performed with a StepOne-
Plus real-time PCR system (Applied Biosystems) and correspond-
ing software. Absolute amounts of Ova and CD8a amplicons, in
arbitrary units, were determined using serial dilutions of pAAV–
CMV–OVA plasmid or pTOPO-CD8a plasmid as a standard. The
datawere expressed asOva/CD8a ratios, ﬁxed at 1 for PBS-injected
control mice.
For quantiﬁcation of Ova mRNA, 100 ng of total RNA were
reverse transcribed using iScript DNA Synthesis Kit (Biorad).
Then, 2μl of cDNA were subjected to real-time PCR ampliﬁca-
tion using Ova primers, β-actin-F (5′-AAG ATC TGG CAC CAC
ACC TTC T-3′) and β-actin-R (5′-TTT TCA CGG TTG GCC TTA
GG-3′) primers. For all reaction mixtures, 10 μl of FastStart Uni-
versal SYBR green master mix (Roche) was used in a ﬁnal volume
of 20μl, Ova primers were used at 500 nM and β-actin primers at
400 nM. The same qPCR program as above-described conditions
were used. The absolute amount of Ova mRNA for each sample
was then normalized against the β-actin mRNA amount (arbitrary
units) and determined using serial dilutions of pAAV–CMV–OVA
plasmid and β-actin puriﬁed PCR product.
FLOW CYTOMETRY AND ELISPOT ASSAYS
Fluorescently labeled anti-CD4 (RM4-5), -CD8 (53-6.7), -CD44
(IM7), -CD62L (MEL-14), -PD-1 (J43), -PD-L1 (B7-H1), -PD-
L2 (B7-DC) monoclonal antibodies (mAb), and unlabeled anti-
CD16/CD32 antibodies were all purchased from eBioscience.
PE-conjugated H-2Kb/Ova257–264 pentamers were used to detect
the CD8+ cells that speciﬁcally recognize the immunodominant
Ova-derived SIINFEKL peptide using the manufacturers’ protocol
(Proimmune). Flow cytometry measurements of single cell sus-
pensions derived from lymphnodes, spleen,or blood sampleswere
performed using standard procedures and acquired on a FACS-
Canto (BDBiosciences) instrument. Flow cytometry analyses were
performed using the FlowJo software (Tree Star).
Enzyme-linked immunospot (ELISpot) assays were performed
following the instructions of the manufacturer (Diaclone). Brieﬂy,
PVDFmembrane plates were coatedwith capture antibody against
mouse IFNγ and blocked with a 2% skimmed milk solution
prepared in PBS. 2× 105 Splenocytes per well were cultured
in vitro for 36 h in the presence of 10μg/ml SIINFEKL pep-
tide. Plates were revealed after incubation with anti-mouse IFNγ
detection antibody coupled to biotin followed with a streptavidin–
alkaline phosphatase conjugate and exposure to a ready-to-use
solution of nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro-
3′-indolyphosphate (BCIP) for chromogenic development. Plates
were analyzed with an ELISpot plate reader and a dedicated
ImmunoSpots software (C.T.L.).
DATA REPRESENTATION AND STATISTICAL ANALYSIS
Results were expressed as mean± SEM. Signiﬁcance was assessed
by non-parametric one-way ANOVA (Kruskal–Wallis tests) using
the GraphPad Prism software. Results were considered statistically
signiﬁcant when the p value was inferior to 0.05 (*), to 0.01(**) or
to 0.001 (***).
RESULTS
CHARACTERIZATION OF THE ANTI-Ova CELLULAR AND HUMORAL
IMMUNE RESPONSES AFTER rAAV2/1-Ova OR rAAV2/8-Ova-MEDIATED
MUSCLE GENE TRANSFER
Weused rAAV2/1-Ova and rAAV2/8-Ova administration tomodel
a gene therapy setting where the transgene encodes for a highly
immunogenic secreted protein. We ﬁrst evaluated the capacity of
these vectors to transduce muscle cells upon direct i.m. injection.
Injection of 1011 viral genome (vg) rAAV2/1-Ova or rAAV2/8-
Ova similarly resulted in efﬁcient transduction, as attested by
the detection of Ova DNA and mRNA in the injected mus-
cles quantiﬁed by qPCR and qRT-PCR respectively (Figure 1A).
No signiﬁcant difference was found when comparing the trans-
duction efﬁciency of rAAV2/1-Ova and rAAV2/8-Ova in these
conditions.
Transgene expression in muscle was found to be high early after
transduction but rapidly declined over time, suggesting the occur-
rence of an immune response against transduced cells (Figure 1A).
To investigate this point, we quantiﬁed the cellular and humoral
immune responses directed against the xenogenic Ova transgene
product by ﬂow cytometry and ELISA. Staining with MHC-I pen-
tamers presenting the immunodominant Ova-derived SIINFEKL
peptide, designated hereafter as H-2Kb/Ova pentamers, allowed to
monitor the expansion of CD8+ lymphocytes in spleen and drain-
ing lymph nodes of rAAV-Ova challenged animals. This analysis
revealed that both rAAV2/1-Ova and rAAV2/8-Ova injected in the
gastrocnemius muscles induced a robust expansion of anti-Ova
CD8+ lymphocytes (Figures 1B,C). Interestingly, the kinetics and
intensity of T cell priming was found to be different when com-
paring the cells harvested from the draining lymph nodes and
from the spleen. In the lymph nodes draining the injected mus-
cles, anti-Ova CD8+ T cells expanded early after AAV challenge
to reach around 2% of the CD8+ T cell compartment at day 7
post-injection (Figure 1C, left panel). In contrast, when analyz-
ing splenocytes, anti-Ova CD8+ T cells were found to reach up
to 10% of the total CD8+ subset but only at day 14 after i.m.
AAV injection (Figure 1C, right panel). These results are consis-
tent with a model in which the local cellular immune response
measured in the draining lymph nodes would be induced by an
rAAV leakage from the injected muscle and the consequent trans-
duction of non-muscle cells such as dendritic cells, as shown for
AAV5 (Xin et al., 2006) or AAV1 (Lu and Song, 2009) for instance.
The systemic response detected in the spleen would rather reﬂect
systemic immunization directed against the circulating sOva pro-
tein after it has been produced by transduced muscle cells. This
interpretation is supported by the kinetics of sOva apparition and
antibodies production (Figure 1D). Indeed, in the serum of AAV-
treated mice, sOva reached a maximum at day 7 post-injection
and rapidly declined thereafter (Figure 1D, green curves). Consis-
tently, anti-Ova IgG appeared between day 7 and 12 after AAV i.m.
injection, correlating with the disappearance of sOva in the serum
after day 7 (Figure 1D, blue curves). The latter probably reﬂects
the in vivo clearance of sOva following the formation of antigen–
antibody immune complexes, although we cannot completely rule
out that anti-Ova IgG antibodies may mask Ova epitopes in the
immunoassay. Together, these data reveal that i.m. injection of
www.frontiersin.org September 2011 | Volume 2 | Article 199 | 3
Adriouch et al. CTLA-4/Ig and AAV-PDL1/2 in gene therapy
FIGURE 1 | Characterization of anti-Ova immune responses following
muscle gene transfer using rAAV2/1-Ova or rAAV2/8-Ova. Group of four
to seven mice were injected with titrated 1×1011 viral genomes (vg) of
either rAAV2/1-Ova or rAAV2/8-Ova in the gastrocnemius muscles at day 0
and then culled at different time points. (A) Gastrocnemius muscles were
analyzed for the presence of Ova DNA and mRNA by qPCR and qRT-PCR,
respectively, at 7, 14, and 40 days post-gene transfer. (B) Representative
ﬂow cytometry proﬁle and (C) bar graphs showing the percentage of
Ova-speciﬁc CD8+ T cells positively stained with H-2Kb/Ova pentamers in
draining lymph nodes and spleen at different time points after gene
transfer. (D) Sera were harvested from individual mice at different time
points and analyzed by ELISA for the detection of sOva (green lines) and
anti-Ova IgG (blue lines).
rAAV encoding sOva is strongly immunogenic and provides a
mouse model that is suited to stringently evaluate the efﬁcacy
of tolerance induction protocols.
CTLA-4/Ig BUT NOT PD-L1 GENE TRANSFER PREVENTS THE PRIMING OF
THE IMMUNE RESPONSES FOLLOWING rAAV2/1-Ova ADMINISTRATION
We investigated the possibility to block immune responses directed
against the transgene product by two distinct immunomodulatory
strategies, one blocking lymphocyte priming (i.e., CTLA-4/Ig) and
the other inhibiting the function of lymphocytes targeting trans-
ducedmuscle ﬁbers (i.e., activation of the PD-1 pathway bymuscle
gene transfer of PD-1 ligands). Indeed, we have previously shown
in transgenic mice that express Ova as a neo-autoantigen in mus-
cle that tolerant transgenic anti-Ova CD8+ T cells up-regulated
PD-1, suggesting that PD-1 plays a role in the induction of tol-
erance to skeletal muscle-expressed Ag (Calbo et al., 2008). As
expected, the anti-Ova CD8+ T cell response that followed an
i.m. injection of rAAV2/1-Ova (Figures 1B,C) was accompanied
by an up-regulation of PD-1 on CD8+ T cells that exhibit an
activated CD44hi phenotype (Figure 2A). As activated T cells
express PD-1 and PD-1 ligands inhibit their activation and func-
tion, we generated rAAV2/1-PD-L1 and rAAV2/1-PD-L2 vectors
and ﬁrst veriﬁed that they were able to efﬁciently transduce HEK
cells in vitro (Figure 2B). The expected consequence of injecting
these vectors i.m. is that they should not prevent T cell priming
but rather inhibit the cytotoxic activity of T cells directed against
muscle-expressed transgenic proteins.
To investigate the in vivo immunomodulatory potential of
CTLA-4/Ig and rAAV2/1-PD-L1, we either administered 200μg
of CTLA-4/Ig i.p. or co-injected rAAV2/1-PD-L1 i.m. at the same
time as rAAV2/1-Ova, and monitored the cellular and humoral
immune response 14 day after. Results showed that even a single
dose of CTLA-4/Ig was efﬁcient to completely prevent the priming
of anti-OvaCD8+ Tcells (Figure 2C, left panel) and the apparition
of anti-Ova IgG in the serumof treated animals (Figure 2C,middle
panel). Accordingly, this immunosuppressive treatment allowed a
sustained sOva production that could be assayed in the serum at
day 14 whereas it was undetectable in controls (Figure 2C right
panel). We concluded from these data that transient immunosup-
pression by a single dose of CTLA-4/Ig is very efﬁcient to prevent
the priming of the cellular and humoral response at early time
points after AAV transduction.
In contrast, despite a slight but not statistically signiﬁcant ten-
dency to reduce immune responses, rAAV2/1-PD-L1 co-injected
with rAAV2/1-Ova failed to provide the same effect on immune
priming (Figure 2C, left and middle panels). Also, treatment with
rAAV2/1-PD-L1 did not allow the persistence of sOva in the serum
in agreementwith the signiﬁcant amount of anti-Ova IgGdetected
in the serum of these animals (Figure 2C). This expected result
conﬁrmed that local transduction of muscle cells with rAAV2/1-
PD-L1 cannot interferewith the systemic immunepriming against
sOva since activation of the PD-1/PD-L1 pathway was anticipated
to regulate T cells functions rather than their priming.
We further analyzed the presence of Ova DNA and mRNA
in muscles at day 40 in the different groups of treated mice by
qPCR and qRT-PCR, respectively. This further conﬁrmed that
suppression of immune priming by CTLA-4/Ig promotes the per-
sistence of transduced cells in vivo as measured by the detection
of signiﬁcantly higher levels of Ova DNA and mRNA in the
muscles of treated animals (Figure 2D). By contrast, injection
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FIGURE 2 | A single injection of CTLA-4/Ig dramatically inhibits
immune responses and improves transgene persistence at early
time points. (A) Mice were injected as in Figure 1 with 1×1011 vg
rAAV2.1-Ova in the gastrocnemius muscles at day 0. Splenic CD8+ T cells
were analyzed at day 14 by ﬂow cytometry for expression of CD44 and
PD-1. (B) rAAV2/1-PD-L1 and rAAV2/1-PD-L2 vectors were designed,
produced, and tested for their capacity to transduce HEK-293 cells
in vitro. For this, cells were analyzed by ﬂow cytometry 3–5 days after
their transduction with 1/10th dilution of the concentrated virus stocks.
Controls correspond to unmanipulated HEK-293 parental cells stained
with the same antibodies (green histograms). (C)The
immunosuppressive potential of rAAV2/1-PD-L1 and CTLA-4/Ig were
evaluated in vivo. Mice were injected with 1011 vg rAAV2/1-Ova in the
gastrocnemius muscles and received or not a co-injection of 1011 vg
rAAV2.1-PD-L1, or 200μg of CTLA-4/Ig injected contemporaneously by
the i.p. route. Blood samples were then collected 14 days later to analyze
the percentage of anti-Ova CD8+ T cells, the level of anti-Ova IgG and the
presence of sOva in the serum. (D) Gastrocnemius muscles were then
collected at day 40, and Ova DNA and mRNA were quantiﬁed by qPCR
and qRT-PCR.
of rAAV2/1-PD-L1 did not signiﬁcantly improve transgene
persistence in these settings, in line with the prominent systemic
immune response detected at day 14 (Figure 2D).
COMBINED TREATMENT WITH CTLA-4/Ig AND rAAV2/1-PD-L1
SYNERGISTICALLY ACTS TO IMPROVE TRANSGENE PERSISTENCE AND
EXPRESSION
Whereas a single dose of CTLA-4/Ig was efﬁcient to suppress
the systemic immune response at day 14 (Figures 3A,B left pan-
els), this was not the case when further monitoring the immune
response at day 40. Indeed, anti-OvaCD8+ T cell expansion aswell
as anti-Ova IgG immune responses were readily detectable at day
40 in mice that had received rAAV2/1-Ova and CTLA-4/Ig at day 0
(Figures 3A,B). Therefore, early suppression of immune prim-
ing by a single dose of CTLA-4/Ig is not sufﬁcient to permanently
wipe out the immune responses against transgene product in these
experimental conditions. Instead, continuous production of sOva
by transduced muscle cells sensitizes the immune response at later
time points when CTLA-4/Ig has been cleared from the circulation
of treated mice.
We next tested whether rAAV2/1-PDL-L1 or rAAV2/1-PDL-L2
could synergize with CTLA-4/Ig to improve transgene tolerance
at later time points when the initial CTLA-4/Ig monotherapy was
evidently not efﬁcient alone to completely block immune sensi-
tization against sOva. This combined strategy may indeed target
two non-redundant mechanisms of immunomodulation acting
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FIGURE 3 | Combination therapies using CTLA-4/Ig and
rAAV-PD-L1 or rAAV-PD-L2 significantly improve transgene
persistence and transcription. Mice were injected with 1×1011 vg
rAAV2/1-Ova in the gastrocnemius muscles at day 0 and received at
the same time an immunomodulatory regimen consisting of either
200μg of CTLA-4/Ig alone or the same amount of CTLA-4/Ig together
with 1×1011 vg rAAV2/1-PD-L1 or rAAV2/1-PD-L2. (A) Blood samples
were collected at day 14 and 40 to evaluate the percentage of CD8+ T
cells speciﬁcally recognizing the immunodominant epitope derived
from Ova by ﬂow cytometric analyses. (B) Sera were collected at days
14, 40, and 80 to assay the level of anti-Ova IgG antibodies by ELISA.
(C) Injected gastrocnemius muscles were collected at day 80 and
analyzed for the presence of Ova DNA and mRNA by qPCR and
qRT-PCR respectively.
either on the APC side for CTLA-4/Ig or on the target tissue side
for rAAV2/1-PD-L1 and rAAV2/1-PDL-L2. To test this possibil-
ity, groups of mice were transduced i.m. with rAAV2/1-Ova and
also received at the same time either rAAV2/1-PD-L1 or rAAV2/1-
PD-L2 i.m. and CTLA-4/Ig i.p. combination therapies. We then
evaluated the cellular and humoral immune responses at differ-
ent time points and ﬁnally evaluated the persistence of transduced
muscle cells by quantiﬁcation of Ova DNA and mRNA at day 80
(Figure 3).
Remarkably, whereas CTLA-4/Ig alone was inefﬁcient,
rAAV2/1-PD-L1 co-administered with CTLA-4/Ig at day 0 sig-
niﬁcantly improved transgene persistence, as measured by quan-
tiﬁcation of Ova DNA by qPCR (Figure 3C, left panel). Accord-
ingly, mRNA analysis by qRT-PCR at day 80 revealed sustained
transcription of the transgene in muscle (Figure 3C, right panel).
Of note, rAAV2/1-PD-L2 appeared equally as effective as rAAV2/1-
PD-L1 to provide this effect when combined with CTLA-4/Ig.
Importantly, this protective effect occurred in a setting where nei-
ther CTLA-4/Ig alone nor the tested combination therapies could
block immune response at days 40 and 80 (Figures 3A,B). To fur-
ther attest the presence of functional anti-Ova cytotoxic T cells
at day 80 (a time point when pentamer staining is not sensitive
enough to detect anti-Ova T cells, not shown), we analyzed by
ELISpot the capacity of CD8+ T cells to secrete IFNγ when stimu-
lated with the Ova-derived immunodominant SIINFEKL peptide.
This assay revealed the presence of low numbers of functional
anti-Ova CD8+ T cells in the three groups of animals that had
receivedCTLA-4/Ig with orwithout rAAV-PD-L1 or rAAV-PD-L2,
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whereas the assay was negative for mice that did not receive rAAV-
Ova and strongly positive for those that received rAAV-Ova in the
absence of any immunoregulatory adjuvant therapy (Figure 4A).
To deﬁnitively demonstrate that these IFNγ-secreting T cells were
functional in vivo, we performed adoptive transfer experiments
to non-lethally irradiated syngenic recipients that were inoculated
with Ova-bearing tumor cells. Whereas tumors rapidly developed
in recipients that had received T cells from control mice that only
receivedPBS, recipientmice receiving lymphocytes fromrAAV2/1-
Ova injected donors rapidly developed an anti-tumor immune
response that resulted in complete tumor rejection (Figure 4B).
In agreement with the lower numbers of anti-Ova CD8+ T cells
detected by ELISpot, recipient mice that had received immune
cells from donors treated with CTLA-4/Ig or the combined CTLA-
4/Ig plus rAAV-PD-L1 or rAAV-PD-L2 therapy reacted with a
slight delay but were also was also capable to efﬁciently control
tumor growth (Figure 4B). Together, these results indicate that
the cytotoxic activity of transgene product speciﬁc T cells that
have escaped costimulation blockade can be functionally blocked
by AAV-mediated gene transfer of PD-1 ligands in muscle tissues
while they remain capable to reject tumor cells.
DISCUSSION
Gene therapy for muscular dystrophies and other monogenic dis-
eases aims at achieving long-term expression of a functional form
of an otherwise deﬁcient gene in target tissues. In this context, the
product of the therapeutic gene is structurally different from its
abnormal or absent counterpart, and consequently viewed as non-
self by the immune system.Additional signals from the viral vector
may further strengthen adverse innate and adaptive immune reac-
tions against the transgene product, while the vector itself can be
targeted by antiviral pre-existing or acquired immunity. Although
the presence of natural epitopes in the non-mutated regions of the
protein or the occasional occurrence of mutation reversion in a
minute population of patients’ cells (Klein et al., 1992) may yield
some level of immunological tolerance, it remains that acquired
immunity to the transgene product still represents one of the
major obstacles to the success of gene therapy. Here, we pro-
vide the proof of principle that a combination immunoregulatory
therapy targeting two non-redundant checkpoints of the immune
response, i.e., priming and effector functions, can promote per-
sistence of transduced target cells and transgene transcription
thereof even when some cytotoxic T cells have escaped initial
control.
A ﬁrst strategy for the blockade of adaptive immunity is obvi-
ously to target costimulation pathways and therefore provide an
early control on lymphocyte priming. Whereas several costimu-
latory pathways have now been identiﬁed, CD28-mediated T cell
costimulation byAPC expressing CD80/CD86 molecules from the
B7 family is clearly prominent. Indeed, CD28 signaling strongly
enhances T cell proliferation and survival, cytokine production
and prevents induction of anergy after TCR-mediated activation
(Boise et al., 1995). Consequently, anti-CD80 (B7.1) or anti-CD86
(B7.2) antibodies inhibit T cell priming and genetically engineered
CD28-deﬁcient T cells are strongly impaired in their capacity to
expand (Green et al., 1994; Salomon and Bluestone, 2001). T cells
activation also promotes up-regulation of the negative regulator
CTLA-4, another ligand of CD80 and CD86 molecules, which
transmits inhibitory signals that regulate activated T cell and pro-
vides a key homeostatic mechanism of the immune response (Fife
and Bluestone, 2008). One of the early striking evidence of the key
role of this molecule is that CTLA-4-deﬁcient animal rapidly die
FIGURE 4 | Detection of anti-OvaT cells in animals treated with
combination therapies. Seven mice per group were injected with
1×1011 vg rAAV2/1-Ova in the gastrocnemius muscles at day 0 and
received at the same time combination therapies as in Figure 3.
Splenocytes were then harvested 80 days after and analyzed for the
presence of lymphocytes capable to respond to Ova antigen. (A)
Splenocytes were analyzed by ELISpot as described in the Section
“Materials and Methods” for their capacity to secrete IFNγ after in vitro
restimulation with the Ova-derived immunodominant SIINFEKL peptide.
(B) 5×107 Splenocytes from the same mice were also adoptively
transferred to 5 Gy-irradiated syngenic mice inoculated 1 day after with
Ova-bearing EG7 tumor cells. The capacity of transferred lymphocytes to
reject the tumors was monitored three times per week by measuring the
tumor size with a digital caliper.
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from massive lymphoproliferative syndrome and dysregulation of
immunity (Waterhouse et al., 1995).
One convenient way to pharmacologically block the CD28
costimulation pathway is to use the soluble CD80/CD86 ligand
CTLA-4/Ig. This fusion protein prevents CD28 interaction with
CD80 and CD86 molecules on naïve and activated T cells and
therefore provides a strong and early inhibition on T cell prim-
ing (June et al., 1990; Lenschow et al., 1992; Larsen et al., 2005).
CTLA-4/Ig may also induce a negative signalization on the APC
side through the induction of indoleamine2,3-dioxygenase (IDO)
which catalyses the production of inhibitory kynurenine from
tryptophan (Grohmann et al., 2002). CTLA-4/Ig may also possibly
provide some level of APC depletion in vivo, although this aspect
has been poorly documented and should critically depend on the
form of CTLA-4/Ig used. Importantly, CTLA-4/Ig is now clinically
available for the treatment of diseases such as rheumatoid arthritis
(Dumont, 2004) and it is thus reasonable to propose its evaluation
in the ﬁeld of gene therapy. Indeed, there has been experimen-
tal evidence that CTLA-4/Ig in combination with a monoclonal
antibody to CD40L (MR1) in the context of gene therapy can
block immune responses and allow vector readministration in the
mouse (Halbert et al., 1998; Lorain et al., 2008). It is difﬁcult to
weight the relative roles of CTLA-4/Ig and MR1 in these experi-
ments but a plausible hypothesis is that CTLA-4/Ig provides the
strongest immunoregulatory contribution since MR1 alone has
been reported to be less efﬁcient in similar experimental con-
ditions (Manning et al., 1998). The results reported herein are
consistent with these earlier reports and provide deﬁnitive evi-
dence that CTLA-4/Ig alone efﬁciently, but only transiently, blocks
anti-transgene T cell priming.
One concern about using CTLA-4/Ig in gene therapy is that
discontinuation of treatment exposes patients to immunization
against the transgene product. The present results illustrate this
point since initial CTLA-4/Ig efﬁciently blocks the anti-Ova cellu-
lar and humoral responseswhile sustained sOva production ﬁnally
elicits this undesired responsewhenCTLA-4/Ig is probably cleared
from the circulation. Our experimental conditions have been pur-
posely designed to model this very situation where the immune
response escapes the initial immunoregulatory regimen in order
to evaluate if a second strategy could provide additional protection
of transduced cells, i.e., PD-L1/2 gene therapy.
The PD-1/PD-L1 pathway has recently been identiﬁed as a
negative regulator of immunity (Sharpe et al., 2007). The PD-1
immunoreceptor is also a member of the CD28/CTLA-4 family
which, upon interaction with either one of its two ligands PD-
L1 or PD-L2, down-modulates TCR signaling, reduces cytokine
production and affects T cell survival by recruiting the SHP-2 tyro-
sine phosphatase, thereby dampening the PI3K and Akt pathway
(Francisco et al., 2010). In BALB/c mice, PD-1 deﬁciency leads to
the spontaneous development of a lethal autoimmune cardiomy-
opathy (Nishimura and Honjo, 2001). This disease is mediated
by autoantibodies directed against the cardiac muscle autoantigen
troponin I (Okazaki et al., 2003). Hence, PD-1 controls the physio-
logical tolerance to muscle autoantigens. Also, PD-L1 was recently
shown to regulate CD8+ T cell-mediated muscle injury in a mouse
model of myocarditis (Grabie et al., 2007). Several PD-1/PD-
L1 dependant mechanisms may act synergistically to induce an
effective effector T cell blockade and contribute to tolerance induc-
tion. As mentioned earlier, PD-1 engagement on the surface of T
cell is known to signiﬁcantly inhibit TCR signaling thereby pre-
venting T cell activation and cytokine production. In addition to
this mechanism, PD-L1 was recently shown to be a potent inducer
of adaptive Tregs. Indeed,PD-L1 expressed onCD8+ dendritic cell
subset plays an important role on the conversion of naive lympho-
cytes toward FoxP3+ regulatory T cells (Wang et al., 2008). Thus,
engagement of PD-1 on T cells could induce cell-intrinsic toler-
ance (by blocking TCR signaling) as well as a dominant form of
immunological tolerance by promoting the emergence of FoxP3+
adaptive Tregs. Of note, manipulation of the PD-1/PD-L1 axis is
also used by some tumors cells to tolerize surrounding lympho-
cytes. Indeed, expression of PD-L1 on the surface of malignant
cells has been suggested to represent a subversive strategy used by
tumors to escape to immuno-surveillance (Iwai et al., 2002). Thus,
we believe that up-regulation of the expression of PD-L1 on the
surface of muscle cells by the means of gene transfer should be
able to induce tolerization of the immune system by preventing
cytotoxicity of PD-1-expressing activated lymphocytes. However,
PD-L1 gene transfer alone was not sufﬁcient in our model to pre-
vent the immune response directed against transduced muscle
ﬁbers (Figure 2), suggesting that muscle expression of PD-L1, i.e.,
at distance from lymphoid compartments, is probably not capable
of inducing sufﬁcient adaptive FoxP3+ Tregs. Another explana-
tion would be that PD-L1 expressed in muscle is not effective to
block fully activated T cells that have received normal costimula-
tory signals (i.e., in the absence of CTLA-4/Ig co-administration).
This interpretation would be in line with the ﬁnding that PD-
1 inhibitory pathway could be overcome by CD28 costimulatory
ligation in the presence of IL-2 (Freeman et al., 2000; Latchman
et al., 2001; Carter et al., 2002; Ishida et al., 2002). Hence, the use
of CTLA-4/Ig to block early CD28 costimulatory signaling may
create favorable conditions where escaping T cells could become
sensitive to PD-L1/2. This strengthens the notion that CTLA-4 and
PD-1 signaling represent two distinct pathways acting synergisti-
cally to maintain tolerance (Fife and Bluestone, 2008). As shown
herein, neither CTLA-4/Ig alone nor combination therapies could
block immune response at days 40 and 80 (Figures 3 and 4).
Our results are thus compatible with the notion that the use of
rAAV2/1-PD-L1 or rAAV2/1-PD-L2 in combination with CTLA-
4/Ig, does not completely inhibit the immune priming against
sOva that most probably occurs at distance from the site of trans-
duction (e.g., spleen and/or lymph nodes) but instead provides an
additional protection by disarming lymphocytes within the target
tissue.
It has been argued that the priming of T cells directed to
the transgene product may be somehow defective after rAAV-
mediated gene transfer (Lin et al., 2007a,b).However, in our exper-
imental settings, transduced muscle ﬁbers progressively disappear
in the absence of immunoregulatory treatment (Figure 2D). Fur-
ther, we show that even after CTLA-4/Ig alone or in combination
therapies, an anti-Ova immune response is evidenced in ELISpot
assays and in an in vivo model of tumor rejection upon adop-
tive transfer of T cells in recipient animals (Figure 4). Hence,
forced up-regulation of PD-1 ligands in muscle cells yielded a
level of protection of transduced cells from the cytotoxic assault
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of circulating anti-Ova lymphocytes and provided in combination
therapy a means to prolong transgene persistence and transcrip-
tion. Therefore, CTLA-4/Ig plus PD-L1/2 combination therapy
represents a candidate approach to circumvent the bottleneck of
immune responses directed toward the transgene product andmay
deserve further investigation for non-secreted transgenic protein
models and in larger animals.
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